Item(by='y7', descendants=None, kids=[25034573], score=None, time=1604924221, title=None, item_type='comment', url=None, parent=25033844, text='Pfizer&#x27;s press release with more information: <a href="https:&#x2F;&#x2F;www.businesswire.com&#x2F;news&#x2F;home&#x2F;20201109005539&#x2F;en&#x2F;" rel="nofollow">https:&#x2F;&#x2F;www.businesswire.com&#x2F;news&#x2F;home&#x2F;20201109005539&#x2F;en&#x2F;</a><p>- Vaccine candidate was found to be more than 90% effective in preventing COVID-19 in participants without evidence of prior SARS-CoV-2 infection in the first interim efficacy analysis<p>- Analysis evaluated 94 confirmed cases of COVID-19 in trial participants<p>- Study enrolled 43,538 participants, with 42% having diverse backgrounds, and no serious safety concerns have been observed; Safety and additional efficacy data continue to be collected<p>- Submission for Emergency Use Authorization (EUA) to the U.S. Food and Drug Administration (FDA) planned for soon after the required safety milestone is achieved, which is currently expected to occur in the third week of November<p>- Clinical trial to continue through to final analysis at 164 confirmed cases in order to collect further data and characterize the vaccine candidateâ€™s performance against other study endpoints')